Royal Bank Of Canada Neoleukin Therapeutics, Inc. Transaction History

Royal Bank Of Canada

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.68 - $0.91 $264 - $353	389 Added 191.63%	592 $0
Q1 2023 May 15, 2023	SELL	$0.5 - $0.72 $1 - $2	-3 Reduced 1.46%	203 $0
Q4 2022 Feb 14, 2023	SELL	$0.4 - $0.55 $127 - $175	-319 Reduced 60.76%	206 $0
Q3 2022 Nov 14, 2022	BUY	$0.69 - $1.33 $215 - $416	313 Added 147.64%	525 $0
Q2 2022 Aug 15, 2022	SELL	$0.92 - $2.25 $3,174 - $7,764	-3,451 Reduced 94.21%	212 $0
Q1 2022 May 16, 2022	SELL	$1.72 - $5.23 $9,067 - $27,572	-5,272 Reduced 59.0%	3,663 $7,000
Q4 2021 Feb 14, 2022	BUY	$4.65 - $7.75 $14,661 - $24,435	3,153 Added 54.53%	8,935 $43,000
Q3 2021 Nov 15, 2021	SELL	$6.05 - $9.66 $9,855 - $15,736	-1,629 Reduced 21.98%	5,782 $42,000
Q2 2021 Aug 16, 2021	BUY	$9.23 - $13.12 $68,403 - $97,232	7,411 New	7,411 $68,000

199K

Ticker NLTX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 42,579,900
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.